Abbott Laboratories
American global health care and medical device products company
ABT NYSE
ISIN US0028241000 SEC CIK 1800 LEI HQD377W2YR662HK5JX27
Follow Abbott Laboratories
Weekly email: filings, results
Revenue, last quarter
$13B
+14.5% vs same quarter last year
Net income
$920M
−44% vs same quarter last year
EPS, diluted
$0.53
−43.6% vs same quarter last year
Operating cash flow
$1.7B
−37.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $44.3B | $6.5B |
| FY24 | $42B | $13.4B |
| FY23 | $40.1B | $5.7B |
| FY22 | $43.7B | $6.9B |
| FY21 | $43.1B | $7.1B |
| FY20 | $34.6B | $4.5B |
| FY19 | $31.9B | $3.7B |
| FY18 | $30.6B | $2.4B |
| FY17 | $27.4B | $477M |
| FY16 | $20.9B | $1.4B |
| FY15 | $20.4B | $4.4B |
| FY14 | $20.2B | $2.3B |
| FY13 | $19.7B | $2.6B |
| FY12 | $19.1B | $6B |
| FY11 | $21.4B | $4.7B |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 56.4% | 18.2% | 14.7% |
| FY24 | 55.4% | 16.3% | 31.9% |
| FY23 | 55.2% | 16.2% | 14.3% |
| FY22 | 56.1% | 19.2% | 15.9% |
| FY21 | 57% | 19.6% | 16.4% |
| FY20 | 56.6% | 15.5% | 13% |
| FY19 | 58.5% | 14.2% | 11.6% |
| FY18 | 58.4% | 11.9% | 7.7% |
| FY17 | 54.7% | 5.7% | 1.7% |
| FY16 | 56.4% | 14.5% | 6.7% |
| FY15 | 57.1% | 14.1% | 21.7% |
| FY14 | 54.5% | 12.8% | 11.3% |
| FY13 | 53.2% | 10.9% | 13.1% |
| FY12 | 53.3% | 7.1% | 31.3% |
| FY11 | 53.2% | 7.6% | 22.1% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $7.4B |
| FY24 | $6.4B |
| FY23 | $5.1B |
| FY22 | $7.8B |
| FY21 | $8.6B |
| FY20 | $5.7B |
| FY19 | $4.5B |
| FY18 | $4.9B |
| FY17 | $4.4B |
| FY16 | $2.1B |
| FY15 | $1.9B |
| FY14 | $2.6B |
| FY13 | $2.2B |
| FY12 | $7.5B |
| FY11 | $7.5B |
- Dividends
- Buybacks
Show the numbers
| Year | Dividends | Buybacks |
|---|---|---|
| FY25 | $4.1B | $893M |
| FY24 | $3.8B | $1.3B |
| FY23 | $3.6B | $1.2B |
| FY22 | $3.3B | $3.8B |
| FY21 | $3.2B | $2.3B |
| FY20 | $2.6B | $403M |
| FY19 | $2.3B | $718M |
| FY18 | $2B | $238M |
| FY17 | $1.8B | $117M |
| FY16 | $1.5B | $522M |
| FY15 | $1.4B | $2.2B |
| FY14 | $1.3B | $2.2B |
| FY13 | $882M | $1.6B |
| FY12 | $3.2B | $2.4B |
| FY11 | $2.9B | $77M |
- Abbott Laboratories
- Healthcare median
Show the numbers
| Year | Abbott Laboratories | Healthcare median |
|---|---|---|
| FY25 | 14.7% | −30.6% |
| FY24 | 31.9% | −47% |
| FY23 | 14.3% | −58% |
| FY22 | 15.9% | −80.4% |
| FY21 | 16.4% | −71.9% |
| FY20 | 13% | −62.2% |
| FY19 | 11.6% | −46.3% |
| FY18 | 7.7% | −49.6% |
| FY17 | 1.7% | −45.9% |
| FY16 | 6.7% | −36% |
| FY15 | 21.7% | −38.4% |
| FY14 | 11.3% | −35.5% |
| FY13 | 13.1% | −37.1% |
| FY12 | 31.3% | −29.1% |
| FY11 | 22.1% | −27.9% |